scholarly journals Prognosis of patients with AIDS-associated Kaposi's sarcoma receiving antiretroviral therapy +/- chemotherapy in Kwazulu-Natal, South Africa: an analysis of 1-yr survival data from NCT00380770

2009 ◽  
Vol 4 (S2) ◽  
Author(s):  
TS Uldrick ◽  
A Mosam ◽  
F Shaik ◽  
G Friedland ◽  
D Skadden ◽  
...  
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Survival Data ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Kwazulu Natal

An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi's sarcoma in KwaZulu-Natal, South Africa

2011 ◽  
Vol 22 (11) ◽  
pp. 671-673 ◽  
Author(s):  
A Mosam ◽  
T S Uldrick ◽  
F Shaik ◽  
H Carrara ◽  
J Aboobaker ◽  
...  
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
World Health ◽  
Combination Antiretroviral Therapy ◽  
Chemotherapy Administration ◽  
Kwazulu Natal ◽  
Oncology Centre ◽  
Health Organization

Summary Roll-out of combination antiretroviral therapy (cART) in South Africa should impact on AIDS-associated Kaposi's sarcoma (KS). Government provision began in 2003, with 23% coverage for World Health Organization (WHO) stage IVAIDS in 2006. To assess the effect of cART availability on KS management, we evaluated records from 701 KS patients seen at a tertiary oncology centre in KwaZulu-Natal, South Africa, from 1995 to 2006. Associations between cART use and measures of KS care were evaluated. cART availability was 0% prior to 2001, 9.6% (2001-2003) and 44% (2004-2006). Documentation of HIV status increased incrementally from 65% to 92%. cART was associated with chemotherapy administration: 56% on cART versus 17% not on cART (P < 0.001); and less loss to follow-up, 13% on cART versus 38% not on cART (P < 0.001). cART availability improves the care of AIDS-associated KS. Further increases in cART availability for this population are needed in South Africa.

scholarly journals Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era

2014 ◽  
Vol 135 (11) ◽  
pp. 2644-2652 ◽  
Author(s):  
Julia Bohlius ◽  
Fabio Valeri ◽  
Mhairi Maskew ◽  
Hans Prozesky ◽  
Daniela Garone ◽  
...  
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983–2006)

2009 ◽  
Vol 20 (8) ◽  
pp. 553-556 ◽  
Author(s):  
A Mosam ◽  
H Carrara ◽  
F Shaik ◽  
T Uldrick ◽  
A Berkman ◽  
...  
Keyword(s):  
South Africa ◽  
Kaposi's Sarcoma ◽  
Temporal Trends ◽  
Public Health Problem ◽  
Kaposi’S Sarcoma ◽  
Incidence Rates ◽  
Antiretroviral Drugs ◽  
South Africans ◽  
Kwazulu Natal ◽  
Black South Africans

The aim of the study was to describe the temporal trends in the incidence of Kaposi's sarcoma (KS) in black South Africans in KwaZulu-Natal (KZN). The study was designed as a retrospective record review. The incidence of Kaposi's sarcoma was estimated using administrative records for patients receiving care for KS through public sector oncology clinics in KZN, 1983–2006. Annual age-standardized incidence rates were calculated using provincial census data for the denominator. Age-specific rates were calculated for the pre-AIDS (1983–1989) and for the generalized AIDS epidemic eras (2006). Age-standardized incidence of KS increased in KZN from <1:100,000 in 1990 to at least 15:100,000 in 2006; this increase was observed in both men and women. There was a shift in the peak age-specific incidence rates from the sixth decade of life in the pre-AIDS era to the fourth and fifth decades in the AIDS era. In conclusion, KS is a growing public health problem in KZN, South Africa. These data reinforce the need for comprehensive national access to and roll-out of antiretroviral drugs, given their success in prevention and treatment of KS in first-world settings.

scholarly journals HAART in hand: The change in Kaposi’s sarcoma presentation in KwaZulu-Natal, South Africa

2016 ◽  
Vol 106 (6) ◽  
pp. 611 ◽  
Author(s):  
Levashni Naidoo ◽  
Judith S Jacobson ◽  
Alfred I Neugut ◽  
Ncoza C Dlova ◽  
Anisa Mosam
Keyword(s):  
South Africa ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Kwazulu Natal

scholarly journals The effect of eligibility for antiretroviral therapy on body mass index and blood pressure in KwaZulu-Natal, South Africa

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Aditi Kuber ◽  
Anna Reuter ◽  
Pascal Geldsetzer ◽  
Natsayi Chimbindi ◽  
Mosa Moshabela ◽  
...  
Keyword(s):  
South Africa ◽  
Blood Pressure ◽  
Body Mass Index ◽  
Antiretroviral Therapy ◽  
Body Mass ◽  
Treatment Guidelines ◽  
Causal Effect ◽  
Regression Discontinuity Design ◽  
National Treatment ◽  
Kwazulu Natal

AbstractWe use a regression discontinuity design to estimate the causal effect of antiretroviral therapy (ART) eligibility according to national treatment guidelines of South Africa on two risk factors for cardiovascular disease, body mass index (BMI) and blood pressure. We combine survey data collected in 2010 in KwaZulu-Natal, South Africa, with clinical data on ART. We find that early ART eligibility significantly reduces systolic and diastolic blood pressure. We do not find any significant effects on BMI. The effect on blood pressure can be detected up to three years after becoming eligible for ART.

AIDS-Related Kaposi’s Sarcoma: Evaluation of Potential New Prognostic Factors and Assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naïve From Antiretrovirals

2003 ◽  
Vol 21 (15) ◽  
pp. 2876-2882 ◽  
Author(s):  
Guglielmo Nasti ◽  
Renato Talamini ◽  
Andrea Antinori ◽  
Ferdinando Martellotta ◽  
Gaia Jacchetti ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Survival Rate ◽  
Survival Data ◽  
Highly Active Antiretroviral Therapy ◽  
Kaposi's Sarcoma ◽  
Systemic Disease ◽  
Univariate Analysis ◽  
Kaposi’S Sarcoma ◽  
Staging System ◽  
Clinical Staging

Purpose: To assess potential new prognostic factors and to validate the AIDS Clinical Trials Group (ACTG) for AIDS-related Kaposi’s sarcoma (AIDS-KS) staging system in the highly active antiretroviral therapy (HAART) era. Patients and Methods: We collected epidemiologic, clinical, staging, and survival data from 211 patients with AIDS-KS enrolled in two prospective Italian human immunodeficiency virus (HIV) cohort studies. We included in the analysis all patients with the diagnosis of KS made from January 1996, the time at which HAART became available in Italy. Results: In the univariate analysis, survival was not influenced by sex, age, level of HIV viremia at KS diagnosis, HAART at KS diagnosis (HAART-naïve v HAART-experienced), or type of HAART combination. Regarding ACTG classification, the 3-year survival rate was 85% for T0 patients and 69% for T1 patients (P = .007), 83% for S0 patients and 63% for S1 patients (P = .003), and 83% for I0 patients and 71% for I1 patients (P = .06). In the multivariate analysis, only the combination of poor tumor stage (T1) and poor systemic disease (S1) risk identified patients with unfavorable prognosis. The 3-year survival rate of patients with T1S1 was 53%, which was significantly lower compared with the 3-year survival rates of patients with T0S0, T1S0, and T0S1, which were 88%, 80%, and 81%, respectively (P = .0001). Conclusion: In the era of HAART, a refinement of the original ACTG staging system is needed. CD4 level does not seem to provide prognostic information. Two different risk categories are identified: a good risk (T0S0, T1S0, T0S1) and a poor risk (T1S1).

Sign in / Sign up

Export Citation Format

Share Document